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proliferation in vitro and in vivo
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Introduction: Aromatic (ar-) turmerone is a major bioactive compound of the herb Curcuma longa. It has been
suggested that ar-turmerone inhibits microglia activation, a property that may be useful in treating neurodegenerative
disease. Furthermore, the effects of ar-turmerone on neural stem cells (NSCs) remain to be investigated.
Methods: We exposed primary fetal rat NSCs to various concentrations of ar-turmerone. Thereafter, cell proliferation
and differentiation potential were assessed. In vivo, naïve rats were treated with a single intracerebroventricular (i.c.v.)
injection of ar-turmerone. Proliferative activity of endogenous NSCs was assessed in vivo, by using noninvasive positron
emission tomography (PET) imaging and the tracer [18F]-fluoro-L-thymidine ([18F]FLT), as well as ex vivo.
Results: In vitro, ar-turmerone increased dose-dependently the number of cultured NSCs, because of an increase in
NSC proliferation (P < 0.01). Proliferation data were supported by qPCR-data for Ki-67 mRNA. In vitro as well as in vivo,
ar-turmerone promoted neuronal differentiation of NSCs. In vivo, after i.c.v. injection of ar-turmerone, proliferating NSCs
were mobilized from the subventricular zone (SVZ) and the hippocampus of adult rats, as demonstrated by both [18F]
FLT-PET and histology (P < 0.05).
Conclusions: Both in vitro and in vivo data suggest that ar-turmerone induces NSC proliferation. Ar-turmerone thus
constitutes a promising candidate to support regeneration in neurologic disease.Introduction
Curcumin and ar-turmerone are the major bioactive com-
pounds of the herb Curcuma longa. Although many studies
have demonstrated curcumin to possess antiinflammatory
and neuroprotective properties (reviewed by [1]), to date,
the effects of ar-turmerone remain to be elucidated. For
example, antitumor properties, exerted via the induc-
tion of apoptosis [2] and inhibition of tumor cell invasion
[3], have been attributed to ar-turmerone. Park et al. [4,5]
recently suggested that ar-turmerone also possesses
antiinflammatory properties resulting from the blockade
of key signaling pathways in microglia. Because micro-
glia activation is a hallmark of neuroinflammation and
is associated with various neurologic disorders, inclu-
ding neurodegenerative diseases [6,7] and stroke [8,9],* Correspondence: adele.rueger@uk-koeln.de
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2014ar-turmerone constitutes a promising therapeutic agent
for various neurologic disorders.
The regenerative potential of endogenous neural
stem cells (NSCs) plays an important role in neuro-
degenerative disease and stroke. Endogenous NSCs are
mobilized by cerebral ischemia [10] as well as by
various neurodegenerative diseases [11,12], although their
intrinsic regenerative response is insufficient to enable
functional recovery. The targeted (that is, pharmacologic)
activation of endogenous NSCs has been shown to enhance
self-repair and recovery of function in the adult brain in
both stroke [13,14] and neurodegeneration [15]. Impor-
tantly, NSCs and microglia relevantly interact with each
other, thereby affecting their respective functions [16,17].
Thus, with the perspective of ar-turmerone as a thera-
peutic option in mind, we investigated the effects of
ar-turmerone on NSCs in vitro and in vivo.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Cell culture
NSCs were cultured from fetal rat cortex at embryonic day
14.5, as described previously [18]. Cells were expanded as
monolayer cultures in serum-free DMEM/F12 medium (Life
Technologies, Darmstadt, Germany) with N2 supplement
(Gibco, Karlsruhe, Germany) and fibroblast growth factor
(FGF2; 10 ng/ml; Invitrogen, Karlsruhe, Germany) for 5 days
and were replated in a 24-well plate at 10,000 cells per cm2.
FGF2 was included throughout the experiments.
Ar-turmerone (Fluka, Munich, Germany) was added to
cultures at replating at concentrations of 0, 1.56, 3.125,
6.25, 12.5, and 25 μg/ml. All experiments were performed
in triplicate. After 72 hours, representative pictures were
taken by using an inverted fluorescence phase-contrast
microscope (Keyence BZ-9000E). Three images were
taken per well, and cells were counted by using the soft-
ware ImageJ with a threshold of 20 px (National Institutes
of Health, Bethesda, MD, USA, Version 1.47 k).
To determine the ratio of proliferating cells, 10 μM bro-
modeoxyuridine (BrdU; Fluka, Munich, Germany) was
added to cultures for 6 hours, before cells were fixed with
4% PFA. Again, all experiments were performed in tripli-
cate. Cells were stained with mAb against BrdU to identify
proliferating cells (clone BU-33, dilution 1:100; Sigma-
Aldrich, Munich, Germany). For antigen-retrieval before
staining, sections were incubated in 2 N HCl for 30 mi-
nutes. For visualization, FITC-labeled anti-mouse IgG was
used (Invitrogen); all cells were additionally counter-
stained with Hoechst 33342 (Life Technologies). To calcu-
late the ratio of proliferating cells, BrdU-positive cells
were divided by the total cell number in each sample, and
mean values were established among equally treated cells.
To establish its effect on cell survival, ar-turmerone
was added to NSC cultures for 24 hours. To discrimi-
nate between live and dead cells, the live/dead cell-
mediated cytotoxicity kit (Life Technologies, cat. no.
L7010) was used according to the manufacturer’s
instructions. Both viable and dead NSCs were counted
in n = 6 samples per condition, and a ratio of surviving
cells was calculated for each field of view; mean values
were calculated for each concentration tested.
To assess the differentiation potential of NSCs treated
with ar-turmerone, mitogen was withdrawn during the
expansion phase, followed by a differentiation phase of
10 days, in the absence (control) or presence of 6.25 μg/ml
ar-turmerone. Immunocytochemistry with markers for
young neurons (TuJ1), astrocytes (GFAP), and oligodendro-
cytes (CNPase) was used to verify all three differentiated fates
of NSCs, whereas SOX2 marked undifferentiated NSCs.
Real-time quantitative PCR (RT-qPCR)
RNA from cells was isolated by using the RNeasy Mini Kit
(Qiagen, Hilden, Germany). Total RNA concentration andpurity were evaluated photometrically. Total RNA was
converted to c-DNA by reverse transcription with the
Quantitect reverse transcription kit (Qiagen). The primer
used for Ki67 was obtained from Biolegio (Nijmegen,
The Netherlands). The sequences of the primers were
as follows: (a) forward: TCTTGGCACTCACAGTCCAG,
and (b) reverse: GCTGGAAGCAAGTGAAGTCC. The
q-PCR reaction was carried out by using 10 ng total RNA
in a 20-μl reaction (Quantitect Reagents, Qiagen) accor-
ding to the manufacturer’s instructions. The samples were
amplified and quantified on a Rotorgene 2000 (Corbett,
Sydney, Australia) by using the following thermal cycler
conditions: activation: 95°C 10 minutes; cycling: 50 cycles,
step 1: 92°C, 15 seconds, step 2: 52°C, 15 seconds, and
step 3: 72°C, 40 seconds. PCR product integrity was evalu-
ated by melting-point analysis and agarose gel electro-
phoresis. Each sample and gene was normalized to
RPL13a as reference gene [19]. Ki67 mRNA levels were
normalized to endogenous RPL13a expression (ΔCT);
normalized values were then expressed as 2-ΔCt. Mean
values were calculated for treated and untreated cells.
Animals and surgery
All animal procedures were in accordance with the
German Laws for Animal Protection and were approved
by the local animal care committee (Buero der
Tierschutzbeauftragten, MPIfNF, Cologne, Germany), as
well as local governmental authorities (LANUV NRW
84–02.04.2012.A116). Spontaneously breathing male
Wistar rats weighing 290 to 330 g were anesthetized
with 5% isoflurane and maintained with 2.5% isoflurane
in 65%:35% nitrous oxide/oxygen. Throughout surgical
procedures, the body temperature was maintained at
37.0°C with a thermostatically controlled heating pad.
Intracerebroventricular injections
One group of animals (n = 3) underwent a single intra-
cerebroventricular (i.c.v.) injection of 3 mg ar-turmerone
at a concentration of 1 mg/μl. For control, n = 6 rats were
vehicle-injected with the identical volume of normal
saline. Under anesthesia with 1.5% isoflurane, each rat’s
skull was fixated in a stereotaxic frame in plane orienta-
tion. After incision of the skin, the bregma was exposed,
and a burr hole was drilled over the right lateral ventricle
by using the following stereotaxic coordinates: bregma,
AP −0.9 mm; ML, −1.4 mm; and VD, +3.8 mm. Ar-
turmerone dissolved in normal saline, or respectively, pure
saline as control, was injected at 1 μl/min. After injection,
the needle was left in place for another 5 minutes to allow
a distribution of the solution within the ventricles. The
needle was thereafter withdrawn slowly, and the skin
sutured with nonabsorbing silk.
After each procedure, all animals were allowed to
recover from anesthesia and were put back into their
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BrdU injections
In all animals, the tracer bromodeoxyuridine (BrdU) was
injected intraperitoneally for 5 days, starting on the day of
i.c.v. injection, at a concentration of 50 mg/kg per injec-
tion, as described previously [18]. This regimen resulted
in a cumulative dose of 250 mg/kg BrdU per animal.
Positron emission tomography (PET)
[18F]-fluoro-L-thymidine ([18F]FLT) was synthesized as
described previously [20]. Seven days after i.c.v. injection
of ar-turmerone or placebo, respectively, PET imaging
was performed on a microPET Focus 220 scanner
(Concorde Microsystems, Inc., Knoxville, TN, USA;
63 image planes; 1.5-mm full width at the half ma-
ximum). Animals were anesthetized with 5% isoflurane,
maintained with 2% isoflurane in a 65%:35% nitrous
oxide/oxygen atmosphere, and placed in the scanner.
Temperature was monitored by using a rectal probe and
maintained at 37°C ± 0.5°C by a thermostatically con-
trolled water-flow system (Medres, Cologne, Germany).
After a 10-minute transmission scan for attenuation
correction, rats received an intravenous bolus injection
of [18F]FLT (1.0 to 2.2 mCi/rat), and emission data were
acquired for 60 minutes. PET data were reconstructed in
two time frames of 1,800 seconds. The last frame (that
is, minutes 31 to 60 after tracer injection) was used for
image analysis.
Image analysis
PET images were co-registered to anatomic data of a 3D
rat-brain atlas constructed from the brain slices pre-
sented by Swanson [21]. Based on the 3D anatomic data,
ellipsoid volumes of interest (VOIs) measuring 4 mm3
were placed to cover the subventricular zone (SVZ) as well
as the dentate gyrus region of the hippocampus. A stan-
dard uptake value (SUV) was calculated for each VOI,
dividing maximal VOI activity by the decay-corrected
injected radioactive dose per body weight. SUVs were
individually determined and then averaged between
animals within each group.
Immunohistochemistry
After PET imaging, or 7 days after ar-turmerone treat-
ment, rats were deeply anesthetized and decapitated.
The brains were rapidly removed, frozen in isopentane,
and stored at −80°C before further histologic and immu-
nohistochemical processing. Ten-μm-thick adjacent ser-
ial coronal brain sections were cut at 500-μm intervals
and stained with anti-BrdU to identify proliferating cells
(mAb clone BU-33, dilution 1:200; Sigma-Aldrich), or
with anti-doublecortin (DCX) to identify neuroblasts(rabbit polyclonal, dilution 1:1,000, Sigma-Aldrich). For
antigen-retrieval before BrdU staining, sections were
microwave-heated in 0.01M citrate buffer, pH 6.0, for
5 minutes, followed by 2 N HCl at 37°C for 30 minutes.
For visualization, the ABC Elite kit (Vector Laboratories
with diaminobenzidine (Sigma-Aldrich) as the final
reaction product was used.
To quantify the width of the SVZ and of the dentate
gyrus of the hippocampus, it was measured on three
consecutive BrdU-stained slices per animal, and an ave-
rage was calculated per animal. To quantify the number
of neuroblasts in the SVZ, their number was counted on
three consecutive DCX-stained slices within a standar-
dized field-of-view for each animal. For both schemes of
quantification, mean values were calculated for each
group of animals.Statistical analysis
Descriptive statistics were performed with Microsoft
Excel 2003 (Microsoft Corp., Redmond, WA, USA).
One-way ANOVA tests (followed by Holm-Sidak post
hoc test) were performed with SigmaPlot 11.0 for
Windows (Systat Software Inc., San Jose, CA, USA).
Statistical significance was set at P < 0.05.Results
Effects on NSC proliferation in vitro
To assess the effects of ar-turmerone on NSC in primary
culture, rat fetal NSC were grown in the presence of
various concentrations of ar-turmerone for 72 hours.
Cell numbers significantly increased when NSCs were
treated with 3.125 to 25 μg/ml ar-turmerone (P < 0.05),
with a maximum increase of NSC numbers by ~80% at
6.25 μg/ml (Figure 1A; P < 0.01).
With the BrdU-incorporation assay, we next investi-
gated whether this increase in NSC number was caused
by an increase in NSC proliferation. Indeed, treatment
with certain concentrations of ar-turmerone significantly
increased the percentage of proliferating NSCs from ~50%
to ~80% (Figure 1B; P < 0.01). This result was verified on
the mRNA level by using qPCR for the proliferation
marker Ki67. In line with the BrdU data, treatment with
6.25 μg/ml ar-turmerone led to a significant increase in
Ki67 mRNA (Figure 1C; P < 0.05).
To assess whether ar-turmerone affected NSC survival,
viable and dead cells were determined after 24 hours,
and the proportion of surviving cells was quantified for
each concentration of ar-turmerone. Concentrations
between 1.56 and 6.25 μg/ml that had yielded the ma-
ximum effect on NSC proliferation did not affect cell
survival. Higher concentrations of 12.5 and 25 μg/ml led
to a significant decrease in the number of viable NSCs
(Figure 1D; P < 0.05).
Figure 1 Ar-turmerone increases NSC proliferation in vitro. (A) Ar-turmerone significantly increased the numbers of fetal rat NSCs in primary
monolayer culture (mean ± SEM; *P < 0.05, compared with control), dependent on its concentration; representative phase-contrast images are
depicted of NSC-treated without (Aʹ) or with (Aʹʹ) 6.25 μg/ml ar-turmerone (bar represents 200 μm). (B) Ar-turmerone significantly increased
the number of proliferating NSCs, as assessed by BrdU-incorporation (mean ± SEM; **P < 0.01, compared with control), dependent on its
concentration; representative images are depicted of NSCs treated without (Bʹ) or with (Bʹʹ) 3.125 μg/ml ar-turmerone, stained for BrdU-incorporation
(bar represents 200 μm). (C) Treating NSCs with 6.25 μg/ml ar-turmerone led to a significant increase in Ki67 mRNA; mRNA levels were
normalized to endogenous RPL13a expression and calculated with the 2-ΔCt method; data are depicted as mean ± SEM; *P < 0.05. (D) In high
concentrations, ar-turmerone significantly decreased ratio of surviving NSCs within 24 hours of treatment, wheres concentrations between
1.56 and 6.25 μg/ml had no effect (mean ± SEM; *P < 0.05, compared with control).
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To assess the effect of ar-turmerone on the differentiation
potential of NSCs in vitro, cells in the expansion phase
were treated with or without 6.25 μg/ml ar-turmerone
and allowed to differentiate for 10 days by withdrawal
of FGF2. Compared with that in untreated control
cells, the differentiation process was significantlyFigure 2 Ar-turmerone induces neurogenesis in vitro and in vivo. (A)
of 6.25 μg/ml ar-turmerone. Immunocytochemistry 10 days after growth-fa
the turmerone-treated group, but more young neurons. The generation of
(mean ± SEM; **P < 0.01, compared with control). (B) Representative image
(left), TuJ1-positive young neurons (middle), and GFAP-positive astrocytes (
ar-turmerone, significantly more DCX-positive neuroblasts were observed in
SEM; **P < 0.01). (D) Representative staining of DCX-positive neuroblasts inaccelerated in ar-turmerone-treated NSCs, with fewer
undifferentiated (SOX2-positive) cells 10 days after
FGF2-withdrawal (Figure 2A; P < 0.01). Moreover,
ar-turmerone-treated NSCs preferentially differenti-
ated into young neurons, as assessed by TuJ1 staining,
compared with untreated control cells (Figure 2A, B;
P < 0.01). The generation of GFAP-positive astrocytesNSCs were allowed to differentiate in the absence (control) or presence
ctor discontinuation revealed fewer undifferentiated (SOX2+) NSCs in
astrocytes and oligodendrocytes was not affected by ar-turmerone
s of differentiated cells include CNPase-positive oligodendrocytes
right); bar represents 50 μm. (C) After i.c.v. injection of 3 mg (1 mg/μl)
the SVZ compared with placebo-injected control animals (mean ±
the SVZ (bar represents 50 μm).
Figure 3 Proliferation of endogenous NSC is induced by ar-turmerone
in vivo. (A) Staining for proliferating NSCs with anti-BrdU demonstrates
that the subventricular zone (SVZ) of rats treated with 3 mg (1 mg/μl)
ar-turmerone i.c.v. (left) was wider than that of placebo-treated control
animals (Aʹ, right); bar represents 100 μm. (B) Differences in the
width of the SVZ were statistically significant (mean ± SEM; *P < 0.05,
compared with control). (C) BrdU staining of the hippocampus did
not reveal a statistically significant increase in the width of the
dentate gyrus, although a trend was noted favoring ar-turmerone
(mean ± SEM).
Hucklenbroich et al. Stem Cell Research & Therapy Page 6 of 92014, 5:100
http://stemcellres.com/content/5/4/100and CNPase-positive oligodendrocytes was unaffected
by ar-turmerone (Figure 2A, B).
To investigate the effects of ar-turmerone on neurogen-
esis in vivo, adult rats were injected with 3 mg ar-turmerone
into the lateral ventricle of the brain (intracerebroventricu-
lar, i.c.v.). One week after treatment, the number of DCX-
positive neuroblasts in the subventricular zone (SVZ) was
significantly increased compared with placebo-injected con-
trol animals (Figure 2C, D).
Proliferation of endogenous NSCs in vivo
The effect of ar-turmerone on endogenous NSCs in vivo
was assessed by injecting adult rats with ar-turmerone
i.c.v. For the following 5 days, rats received daily sys-
temic injections of BrdU to label proliferating cells in vivo.
Immunohistochemistry 1 week after ar-turmerone treat-
ment revealed the SVZ of treated rats to be wider than
that of placebo-injected control animals, as measured
by BrdU staining (Figure 3A). Differences in the size of
the SVZ, as assessed by BrdU-staining, were statistically
significant (Figure 3B; P < 0.05). BrdU-staining of the
hippocampus did not reveal a statistically significant
increase in the width of the dentate gyrus, although a
trend was noted toward a wider dentate gyrus after treat-
ment with ar-turmerone (Figure 3C).
Mobilization of endogenous NSCs from the neurogenic
niches
A noninvasive PET-imaging assay was used to visualize
and quantify the mobilization of endogenous NSCs from
the neurogenic niches of ar-turmerone-treated animals
in vivo. One week after i.c.v. injection of ar-turmerone,
the radiotracer [18F]FLT was injected systemically to
label proliferating endogenous NSCs in vivo, and then
PET data were acquired and co-registered to a 3D rat
brain atlas.
The brains of ar-turmerone-treated rats showed
marked accumulation of [18F]FLT in the SVZ ipsi- and
contralateral to the i.c.v. injection (Figure 4A), compared
with saline-injected control animals (Figure 4B). More-
over, ar-turmerone-treated rats showed significantly
more [18F]FLT-accumulation in both the SVZ and the
hippocampus than the control animals (P < 0.01), thus
indicating a mobilization of proliferating NSCs from
both neurogenic niches (Figure 4C).
Discussion
The data suggest that ar-turmerone increases the proli-
ferative activity of NSCs. Recently, both positive and
negative effects on proliferation have been attributed to
ar-turmerone, dependent on the cell type studied [22].
Although ar-turmerone inhibited the proliferation of
various cancer cell lines, it enhanced proliferation of
peripheral blood mononuclear cells [22]. With theprospect of evaluating ar-turmerone as a drug candidate
for neurodegenerative disorders or stroke, one must keep
in mind that enhancing the proliferation of NSCs, espe-
cially by genetic manipulations, bears a certain oncogenic
risk [23]. However, pharmacologic expansion of the stem
cell niche without genetic manipulations seems to be less
associated with an increased cancer risk [13,14].
Another issue to be considered before promoting the
use of ar-turmerone in clinical studies is that we here
applied ar-turmerone in vivo via i.c.v. injection, a route
that is obviously not applicable in clinical studies.
Figure 4 Endogenous NSCs in the neurogenic niches of the rat brain are mobilized by ar-turmerone in vivo. (A) [18F]FLT-PET of a rat
brain 1 week after intracerebroventricular injection of ar-turmerone shows enhanced accumulation of [18F]FLT in the subventricular zone com-
pared with (B) Saline-injected control brain, indicating an increase of proliferating endogenous NSCs caused by ar-turmerone. (C) Ar-turmerone-
treated rats showed significantly more [18F]FLT accumulation in the SVZ and the hippocampus than did control animals (mean ± SEM; **P < 0.01).
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lity of ar-turmerone after both intravenous or intra-
peritoneal injection in the mouse [24].
In vivo, ar-turmerone expanded the width of the SVZ
by ~45%. An expansion of this NSC niche has also been
demonstrated for other pharmacologic agents such
as growth factors [13,14]. In a similar experimental
setting, we previously observed that FGF2 expanded the
SVZ by ~350%, whereas a combination of the Notch
ligand Delta-like 4 and insulin led to an increase in the
width of the SVZ of ~66% [18]. Our data therefore
suggest that the effect of ar-turmerone on the NSC
niche in vivo is somewhat smaller than that of ”classic”
NSC-activation pathways. Nevertheless, the pleiotropic
effects of ar-turmerone render it a promising drug for
further studies.
Ar-turmerone was recently described to inhibit the
LPS- or Aß-induced activation of microglia through in-
hibition of NF-κB, JNK-, and p38-MAPK pathways [4,5].
Microglia activation as the hallmark of an innate inflam-
matory response of the central nervous system (CNS)
has been found in many neurologic disorders that are
considered to be primarily nonimmunogenic, such as
stroke [25,26], traumatic brain injury (TBI [27], Parkinson
disease [6], or Alzheimer disease [7]. NSC and immune
cells interact extensively [16,17,28-30]. Therefore, thera-
peutically regulating one entity’s fate is likely to influence
the other.Yet, our knowledge about the interaction of NSCs
and inflammatory responses in the CNS with regard to
regeneration and functional recovery to date remains
scarce. On attraction by proinflammatory cytokines,
endogenous NSCs considerably affect this regenerative
response [31,32], for example, through inducing remyeli-
nization [33] and neuroprotection [15]. As ar-turmerone
both limits microglia activation and induces NSC prolife-
ration, it constitutes a promising future drug candidate to
support regeneration in neurologic disorders.
In the presence of mitogen in cell culture, as well as
under physiological conditions in vivo, we found ar-
turmerone to promote neurogenesis. However, after FGF2
discontinuation in vitro, treatment with ar-turmerone led
to an accelerated decrease of undifferentiated NSC, indi-
cating an early exit from the cell cycle. This effect suggests
that ar-turmerone may act as a weak antagonist on the
FGF-receptor only in the absence of the ligand.
Further studies are needed to clarify such a putative
relationship. In support of this notion, a recent report
suggests that ar-turmerone acts as an antagonist on the
related epidermal growth factor (EGF) receptor [34].
Noninvasive in vivo imaging is a crucial tool for transla-
tion from bench to bedside (that is, from experimental
animal to human studies). We used PET imaging and the
radiotracer [18F]FLT that enables imaging and measuring
of proliferation, thereby allowing noninvasive detection
and quantification of endogenous NSC mobilization in the
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of monitoring the effects of drugs aimed at expanding the
NSC niche [35]. By using [18F]FLT-PET, we here found ar-
turmerone to mobilize NSCs from both neurogenic
niches, the SVZ and the dentate gyrus of the hippo-
campus, in vivo. Thus, this study provides further evi-
dence for NSC activation by ar-turmerone, spanning from
cell-culture findings to in vivo imaging.
Conclusions
In this study, we investigated the effects of ar-turmerone
on NSCs in vitro and in vivo. Ar-turmerone increased the
number of NSCs both in cell culture and in the adult rat
brain in vivo. This increase resulted from enhanced NSC
proliferation and led to promoted neurogenesis during
differentiation. In vivo, ar-turmerone mobilized endoge-
nous NSCs from both neurogenic niches, the SVZ and the
hippocampus. We propose that ar-turmerone constitutes
a promising future drug candidate to support regeneration
in neurologic disorders.
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